Medical Department, Technische Universität München, Ismaningerstrasse 22, 81675 Munich, Germany

Biography

Member of the Molecular Tumor Board at Klinikum rechts der Isar of the Technical University of Munich. Specialist in molecular diagnostics and targeted therapies (Molecular Tumor Board)

Publications

• Research Article   
  Rare SARS-CoV-2 Antibody Development in Cancer Patients
  Author(s): Louisa Hempel*, Jakob Molnar, Sebastian Robert, Julia Veloso, Zeljka Trepotec, Sofie Englisch, Philip Weinzierl, Cordula Schick, Valeria Milani, Katrin Schweneker, Bastian Fleischmann, Josef Scheiber, Beate Gandorfer, Axel Kleespies, Wolfgang Kaminski, Dirk Hempel, Kristina Riedmann and Armin Piehler
  
  SARS-CoV-2 antibody development and immunity will be crucial for the further course of the pandemic. Until now, it has been assumed that patients who were infected with SARS-CoV-2 develop antibodies as it is the case with other coronaviruses, like MERS-CoV and SARS-CoV. In the present study, we analyzed the antibody development of 77 oncology patients 26 days after positive RT-qPCR testing for SARS-CoV2. RT-qPCR and anti-SARS-CoV2-antibody methods from BGI (MGIEasy Magnetic Beads Virus DNA/RNA Extraction Kit) and Roche (Elecsys Anti-SARS- CoV-2 immunoassay) were used, respectively, according to the manufacturers’ specifications. Surprisingly, antibody development was detected in only 6 of 77 individuals with a confirmed history of COVID-19. Despite of multiple testing, the remaining patients did not show measurable antibody concentrations in subsequent .. View More»
  

  Abstract PDF